X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (816) 816
Publication (101) 101
Newspaper Article (24) 24
Book / eBook (17) 17
Book Chapter (16) 16
Patent (14) 14
Conference Proceeding (9) 9
Book Review (8) 8
Government Document (5) 5
Dissertation (2) 2
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (310) 310
oncology (259) 259
index medicus (192) 192
male (153) 153
female (148) 148
lung neoplasms - drug therapy (144) 144
carcinoma, non-small-cell lung - drug therapy (125) 125
middle aged (114) 114
aged (110) 110
adult (93) 93
lung neoplasms - pathology (82) 82
cancer (74) 74
lung cancer (74) 74
chemotherapy (71) 71
animals (70) 70
treatment outcome (65) 65
article (64) 64
carcinoma, non-small-cell lung - pathology (63) 63
antineoplastic agents - therapeutic use (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (57) 57
therapy (55) 55
aged, 80 and over (51) 51
mice (46) 46
gefitinib (45) 45
research (44) 44
tumors (41) 41
receptor, epidermal growth factor - antagonists & inhibitors (40) 40
astronomy & astrophysics (39) 39
lung neoplasms - metabolism (39) 39
lung neoplasms - mortality (39) 39
prognosis (39) 39
clinical trials as topic (38) 38
lung neoplasms - genetics (38) 38
expression (37) 37
neoplasms - drug therapy (36) 36
respiratory system (36) 36
antibodies, monoclonal, humanized (34) 34
quinazolines - therapeutic use (34) 34
angiogenesis (33) 33
hematology, oncology and palliative medicine (33) 33
mutation (33) 33
neoplasm staging (33) 33
survival rate (33) 33
carboplatin (32) 32
carcinoma, non-small-cell lung - genetics (32) 32
care and treatment (32) 32
survival analysis (32) 32
antibodies, monoclonal - therapeutic use (31) 31
bevacizumab (31) 31
carcinoma, non-small-cell lung - mortality (31) 31
lung cancer, non-small cell (31) 31
survival (31) 31
cell lung-cancer (30) 30
lung neoplasms - therapy (30) 30
trial (30) 30
breast-cancer (29) 29
clinical trials (29) 29
docetaxel (29) 29
angiogenesis inhibitors - therapeutic use (28) 28
erlotinib (28) 28
patients (28) 28
disease-free survival (27) 27
cell line, tumor (26) 26
paclitaxel (26) 26
tyrosine kinase inhibitor (26) 26
drug therapy (25) 25
growth-factor receptor (25) 25
immunotherapy (25) 25
analysis (24) 24
combination (24) 24
disease progression (24) 24
dose-response relationship, drug (24) 24
mutations (24) 24
phase-iii trial (24) 24
quinazolines - administration & dosage (24) 24
carcinoma, non-small-cell lung - metabolism (22) 22
erlotinib hydrochloride (22) 22
antineoplastic agents - pharmacology (21) 21
carcinoma (21) 21
cetuximab (21) 21
cisplatin (21) 21
health aspects (21) 21
mice, nude (21) 21
abridged index medicus (20) 20
carcinoma, squamous cell - drug therapy (20) 20
endothelial growth-factor (20) 20
paclitaxel - administration & dosage (20) 20
retrospective studies (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
carboplatin - administration & dosage (19) 19
combined modality therapy (19) 19
molecular processes (19) 19
time factors (19) 19
adenocarcinoma (18) 18
antibodies, monoclonal - administration & dosage (18) 18
antineoplastic agents - adverse effects (18) 18
apoptosis (18) 18
biomarkers (18) 18
cancer therapies (18) 18
nivolumab (18) 18
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (6) 6
Gerstein Science - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UTL at Downsview - May be requested (3) 3
UofT at Mississauga - Stacks (2) 2
Art - Library use only (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Despite advances in the treatment of cancer and reductions in smoking rates, lung cancer continues to be one of the leading causes of cancer death... 
Journal Article
Nature, ISSN 0028-0836, 11/2019, Volume 575, Issue 7782, pp. 294 - 295
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii16.2 - vii16
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii5.2 - vii5
Journal Article
Nature, ISSN 0028-0836, 01/2018, Volume 553, Issue 7689, pp. 446 - 454
Journal Article
Biochemistry, ISSN 0006-2960, 03/2019, Volume 58, Issue 12, pp. 1555 - 1557
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 12/2018
Tumor-infiltrating lymphocytes (TIL) are crucial for the success of immunotherapy, and their density can predict prognosis. It has now been shown that... 
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 02/2016, Volume 11, Issue 2, pp. S8 - S8
Journal Article
Cancer, ISSN 0008-543X, 12/2018, Volume 124, Issue 24, pp. 4592 - 4596
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2016, Volume 22, Issue 9, pp. 2102 - 2104
Blockade of the PD-1 axis has emerged as an effective anticancer immunotherapy against various tumor types. Diverse studies have identified biomarkers... 
Neoplasms - metabolism | Immunotherapy - methods | Neoplasms - therapy | Neoplasms - immunology | Humans | Biomarkers, Tumor - metabolism | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal - immunology
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article